Time for risk assessment without borders

In the past few decades, there has been significant improvement in the diagnostic [1] and therapeutic interventions to combat atherosclerotic heart disease (ASCVD) [2]. Despite that, ASCVD remains the leading cause of death both globally and in the United States. In addition, there are significant variations in the prevalence and severity of ASCVD between genders and races. Most often clinicians utilize global risk scores developed and adopted by different professional societies for the assessment of ASCVD risk in asymptomatic patients.

Source: Atherosclerosis - October 20, 2018 Category: Cardiology Authors: Mouaz H. Al-Mallah, Todd C. Villines Tags: Editorial Source Type: research